Literature DB >> 19587776

An improved synthesis of haloaceteamidine-based inactivators of protein arginine deiminase 4 (PAD4).

Corey P Causey1, Paul R Thompson.   

Abstract

Protein arginine deiminase 4 (PAD4) is an enzyme that hydrolyzes peptidyl arginine residues to form citrulline and ammonia. This enzyme has been implicated in several disease states, e.g. rheumatoid arthritis, and therefore represents a unique target for the development of a novel therapeutic. A solution-phase synthesis of Cl-amidine, the most potent PAD4 inactivator described to date, has been developed. This synthesis proceeds in 80% yield over 4 steps at a significantly (12-fold) lower cost.

Entities:  

Year:  2008        PMID: 19587776      PMCID: PMC2597826          DOI: 10.1016/j.tetlet.2008.05.021

Source DB:  PubMed          Journal:  Tetrahedron Lett        ISSN: 0040-4039            Impact factor:   2.415


  19 in total

1.  A fluoroacetamidine-based inactivator of protein arginine deiminase 4: design, synthesis, and in vitro and in vivo evaluation.

Authors:  Yuan Luo; Bryan Knuckley; Young-Ho Lee; Michael R Stallcup; Paul R Thompson
Journal:  J Am Chem Soc       Date:  2006-02-01       Impact factor: 15.419

2.  The diagnostic properties of rheumatoid arthritis antibodies recognizing a cyclic citrullinated peptide.

Authors:  G A Schellekens; H Visser; B A de Jong; F H van den Hoogen; J M Hazes; F C Breedveld; W J van Venrooij
Journal:  Arthritis Rheum       Date:  2000-01

3.  Expression of peptidylarginine deiminase type 4 (PAD4) in various tumors.

Authors:  Xiaotian Chang; Jinxiang Han
Journal:  Mol Carcinog       Date:  2006-03       Impact factor: 4.784

4.  Replication of putative candidate-gene associations with rheumatoid arthritis in >4,000 samples from North America and Sweden: association of susceptibility with PTPN22, CTLA4, and PADI4.

Authors:  Robert M Plenge; Leonid Padyukov; Elaine F Remmers; Shaun Purcell; Annette T Lee; Elizabeth W Karlson; Frederick Wolfe; Daniel L Kastner; Lars Alfredsson; David Altshuler; Peter K Gregersen; Lars Klareskog; John D Rioux
Journal:  Am J Hum Genet       Date:  2005-11-01       Impact factor: 11.025

5.  Citrulline is an essential constituent of antigenic determinants recognized by rheumatoid arthritis-specific autoantibodies.

Authors:  G A Schellekens; B A de Jong; F H van den Hoogen; L B van de Putte; W J van Venrooij
Journal:  J Clin Invest       Date:  1998-01-01       Impact factor: 14.808

6.  Modulation of peptidyl arginine deiminase 2 and implication for neurodegeneration.

Authors:  Sanjoy K Bhattacharya; Manjunatha B Bhat; Hidenari Takahara
Journal:  Curr Eye Res       Date:  2006-12       Impact factor: 2.424

Review 7.  Citrullinated proteins: sparks that may ignite the fire in rheumatoid arthritis.

Authors:  Erik R Vossenaar; Walther J van Venrooij
Journal:  Arthritis Res Ther       Date:  2004-04-19       Impact factor: 5.156

8.  Peptidyl arginine deiminase type 2 (PAD-2) and PAD-4 but not PAD-1, PAD-3, and PAD-6 are expressed in rheumatoid arthritis synovium in close association with tissue inflammation.

Authors:  Céline Foulquier; Mireille Sebbag; Cyril Clavel; Sabine Chapuy-Regaud; Roula Al Badine; Marie-Claire Méchin; Christian Vincent; Rachida Nachat; Michiyuki Yamada; Hidenari Takahara; Michel Simon; Marina Guerrin; Guy Serre
Journal:  Arthritis Rheum       Date:  2007-11

9.  Peptidylarginine deiminase: a candidate factor in demyelinating disease.

Authors:  M A Moscarello; L Pritzker; F G Mastronardi; D D Wood
Journal:  J Neurochem       Date:  2002-04       Impact factor: 5.372

10.  PADI4 polymorphisms and rheumatoid arthritis susceptibility: a meta-analysis.

Authors:  Young Ho Lee; Young Hee Rho; Seong Jae Choi; Jong Dae Ji; Gwan Gyu Song
Journal:  Rheumatol Int       Date:  2007-01-31       Impact factor: 3.580

View more
  20 in total

1.  Citrullination of proteins: a common post-translational modification pathway induced by different nanoparticles in vitro and in vivo.

Authors:  Bashir M Mohamed; Navin K Verma; Anthony M Davies; Aoife McGowan; Kieran Crosbie-Staunton; Adriele Prina-Mello; Dermot Kelleher; Catherine H Botting; Corey P Causey; Paul R Thompson; Ger Jm Pruijn; Elena R Kisin; Alexey V Tkach; Anna A Shvedova; Yuri Volkov
Journal:  Nanomedicine (Lond)       Date:  2012-05-25       Impact factor: 5.307

2.  The development of N-α-(2-carboxyl)benzoyl-N(5)-(2-fluoro-1-iminoethyl)-l-ornithine amide (o-F-amidine) and N-α-(2-carboxyl)benzoyl-N(5)-(2-chloro-1-iminoethyl)-l-ornithine amide (o-Cl-amidine) as second generation protein arginine deiminase (PAD) inhibitors.

Authors:  Corey P Causey; Justin E Jones; Jessica L Slack; Daisuke Kamei; Larry E Jones; Venkataraman Subramanian; Bryan Knuckley; Pedram Ebrahimi; Alexander A Chumanevich; Yuan Luo; Hiroshi Hashimoto; Mamoru Sato; Lorne J Hofseth; Paul R Thompson
Journal:  J Med Chem       Date:  2011-09-16       Impact factor: 7.446

3.  Inhibiting protein arginine deiminases has antioxidant consequences.

Authors:  Erin E Witalison; Xiangli Cui; Anne B Hofseth; Venkataraman Subramanian; Corey P Causey; Paul R Thompson; Lorne J Hofseth
Journal:  J Pharmacol Exp Ther       Date:  2015-01-29       Impact factor: 4.030

4.  Interrogation of the Active Sites of Protein Arginine Deiminases (PAD1, -2, and -4) Using Designer Probes.

Authors:  Angelica M Bello; Ewa Wasilewski; Lianhu Wei; Mario A Moscarello; Lakshmi P Kotra
Journal:  ACS Med Chem Lett       Date:  2013-01-15       Impact factor: 4.345

5.  Anticancer peptidylarginine deiminase (PAD) inhibitors regulate the autophagy flux and the mammalian target of rapamycin complex 1 activity.

Authors:  Yuji Wang; Pingxin Li; Shu Wang; Jing Hu; Xiangyun Amy Chen; Jianhui Wu; Megan Fisher; Kira Oshaben; Na Zhao; Ying Gu; Dong Wang; Gong Chen; Yanming Wang
Journal:  J Biol Chem       Date:  2012-05-17       Impact factor: 5.157

6.  Suppression of colitis in mice by Cl-amidine: a novel peptidylarginine deiminase inhibitor.

Authors:  Alexander A Chumanevich; Corey P Causey; Bryan A Knuckley; Justin E Jones; Deepak Poudyal; Alena P Chumanevich; Tia Davis; Lydia E Matesic; Paul R Thompson; Lorne J Hofseth
Journal:  Am J Physiol Gastrointest Liver Physiol       Date:  2011-03-17       Impact factor: 4.052

7.  Protein arginine deiminase 4: a target for an epigenetic cancer therapy.

Authors:  Jessica L Slack; Corey P Causey; Paul R Thompson
Journal:  Cell Mol Life Sci       Date:  2010-08-13       Impact factor: 9.261

8.  Substrate specificity and kinetic studies of PADs 1, 3, and 4 identify potent and selective inhibitors of protein arginine deiminase 3.

Authors:  Bryan Knuckley; Corey P Causey; Justin E Jones; Monica Bhatia; Christina J Dreyton; Tanesha C Osborne; Hidenari Takahara; Paul R Thompson
Journal:  Biochemistry       Date:  2010-06-15       Impact factor: 3.162

9.  Peptidylarginine deiminase inhibition reduces vascular damage and modulates innate immune responses in murine models of atherosclerosis.

Authors:  Jason S Knight; Wei Luo; Alexander A O'Dell; Srilakshmi Yalavarthi; Wenpu Zhao; Venkataraman Subramanian; Chiao Guo; Robert C Grenn; Paul R Thompson; Daniel T Eitzman; Mariana J Kaplan
Journal:  Circ Res       Date:  2014-01-14       Impact factor: 17.367

10.  Peptidylarginine deiminase inhibition disrupts NET formation and protects against kidney, skin and vascular disease in lupus-prone MRL/lpr mice.

Authors:  Jason S Knight; Venkataraman Subramanian; Alexander A O'Dell; Srilakshmi Yalavarthi; Wenpu Zhao; Carolyne K Smith; Jeffrey B Hodgin; Paul R Thompson; Mariana J Kaplan
Journal:  Ann Rheum Dis       Date:  2014-08-07       Impact factor: 19.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.